Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for N-acetylcysteine  COVID-19 treatment studies for N-acetylcys..  C19 studies: N-acetylcys..  N-acetylcys..   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Melatonin (meta)
Aspirin (meta) Metformin (meta)
Bamlaniv../e.. (meta) Molnupiravir (meta)
Bebtelovimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Cannabidiol (meta) Nitric Oxide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Lactoferrin (meta)

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality 10% Improvement Relative Risk c19early.com/na Delić et al. N-acetylcys.. for COVID-19 RCT ICU Favors N-acetylcysteine Favors control
Delić, 91 patient N-acetylcysteine late treatment RCT: 10% lower mortality [p=0.67] https://c19p.org/delic
copied to clipboard
Effects of Different Inhalation Therapy on Ventilator-Associated Pneumonia in Ventilated COVID-19 Patients: A Randomized Controlled Trial
Delić et al., Microorganisms, doi:10.3390/microorganisms10061118
28 May 2022    Source   PDF   Share   Tweet
RCT mechanically ventilated patients in Croatia, 39 treated with N-acetylcysteine and 52 control patients, showing no significant difference in mortality with treatment. Treated patients showed a lower incidence of gram-positive or MRSA-caused ventilator-associated pneumonia.
risk of death, 9.7% lower, RR 0.90, p = 0.67, treatment 21 of 39 (53.8%), control 31 of 52 (59.6%), NNT 17.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Delić et al., 5/28/2022, Randomized Controlled Trial, Croatia, peer-reviewed, 12 authors, study period October 2020 - June 2021.
Contact: ndelic@kbsplit.hr (corresponding author), tkljakgas@kbsplit.hr, lsaric@kbsplit.hr, dilic@kbsplit.hr, sdosenovic@kbsplit.hr, jdomazet@kbsplit.hr, rkovac@kbsplit.hr, sastojanovic@kbsplit.hr, bduplanc@kbsplit.hr, andrija.matetic@gmail.com, frane.runjic@gmail.com, josipa.domjanovic@gmail.com.
All Studies   All Outcomes
This PaperN-acetylcys..All
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit